APEIKON THERAPEUTICS LTD
ActiveKey figures
Like most small UK companies, APEIKON THERAPEUTICS LTD does not publish a profit and loss account in its latest accounts. The figures below come from the balance sheet.
Ratios
2025Sector comparison
SIC 72110Where the company stands among the 3,991 active companies whose first SIC code is 72110 (Research and experimental development on biotechnology).
- BRACCO HORIZONS LIMITED£526.1m
- TAURX THERAPEUTICS MANAGEMENT LTD.£470.3m
- LABCORP EARLY DEVELOPMENT LABORATORIES LIMITED£317m
- JAZZ PHARMACEUTICALS RESEARCH UK LIMITED£289.2m
- GENOME RESEARCH LIMITED£273.7m
- MODERNA BIOTECH UK LIMITED£236.5m
- CURIA (SCOTLAND) LIMITED£183m
- ASTEX THERAPEUTICS LIMITED£163.6m
- HORIZON DISCOVERY GROUP LIMITED£159.6m
- AMGEN LIMITED£134.4m
Positions are approximate. Figures come from each company's latest accounts; money and employee figures are compared only with companies that filed accounts in pounds for a period ending in the last two and a half years and are not dormant, so those groups are smaller than 3,991. The line on each bar marks the median.
Summary: APEIKON THERAPEUTICS LTD
What kind of company is it?
APEIKON THERAPEUTICS LTD is a private limited company registered with Companies House under company number 13057597. It was incorporated on 2 Dec 2020. Its status is active. The registered office is in London (WC2H). Its nature of business (SIC 2007) is research and experimental development on biotechnology (72110).
How is the company doing financially?
The latest accounts in the database are for 2025 (period ending 31 Dec 2025); the company files small company accounts (filleted). Net assets were £30,259, up 2,307.1% on the previous year. Cash at bank and in hand was £61,683. The company had an average of 0 employees. Figures are available for 5 financial years (2021–2025).
How does it compare with similar companies?
Compared with 3,991 active companies whose first SIC code is 72110: By net assets it ranks higher than 52% of them (median £20,978). By total assets it ranks lower than 60% of them (median £125,654). By cash it ranks lower than 58% of them (median £101,976). By number of employees it ranks lower than 65% of them (median 1). It is older than 53% of them (median age 5.4 years).
Has it received government grants?
It is recorded as the recipient of 2 central government grants worth £126.3k, mainly from Department for Science, Innovation and Technology.
Who runs and controls the company?
The company has 2 current directors.
When are its next filings due?
The next accounts are due by 30 Sep 2027. The next confirmation statement is due by 9 Dec 2026.
Filed accounts2021–2025
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Cash at bank and in hand | 100 | 12,481 | 104,482 | 26,536 | 61,683 |
| Total assets | 100 | 18,327 | 107,768 | 32,180 | 61,869 |
| Total liabilities | — | — | — | — | — |
| Net assets / total equity | 100 | -13,530 | 72,947 | -1,371 | 30,259 |
| Average number of employees | 0 | 1 | 2 | 3 | 0 |
A dash (—) means no accounts were filed for that year or the item is not in the accounts; 0 is a zero stated in the accounts. Small companies usually file only a balance sheet, so the profit and loss account is often missing.
Government grants
2 grantsAPEIKON THERAPEUTICS LTD is recorded as the recipient of 2 central government grants since 2022, together worth £126.3k.
- Department for Science, Innovation and Technology
- 1 grant · £74.5k
- Department for Business, Energy and Industrial Strategy
- 1 grant · £51.8k
- Image-guided, focused ultrasound-triggered drug delivery technology for brain cancersDepartment for Business, Energy and Industrial Strategy · £51,810 · UKRI - Innovate UK - Scheme 22/23
- Image-guided, focused ultrasound-triggered drug delivery technology for brain cancersDepartment for Science, Innovation and Technology · £74,451 · UKRI - Innovate UK - Scheme
From the Government Grants Register published by the Cabinet Office (financial years 2016/17 onwards, Open Government Licence v3.0). It covers grants from central government departments and their agencies where the register states the recipient's company number and the recipient name matches this company; grants from local authorities, lottery distributors and devolved governments are not included.
History
15 events- Financial year 2025 endedAccounts: net assets £30.3k, 0 employees
- Financial year 2024 endedAccounts: net assets −£1,371, 3 employees
- Maral AMRAHLI resignedDirector
- Financial year 2023 endedAccounts: net assets £72.9k, 2 employees
- Dr Moh Tadayyon ceased to be a person with significant control
- Prof. Maria Thanou ceased to be a person with significant control
- OHS SECRETARIES LIMITED appointedSecretary (corporate)
- Maral AMRAHLI appointedDirector
Earlier events (7)
- Financial year 2022 endedAccounts: net assets −£13.5k, 1 employee
- Financial year 2021 endedAccounts: net assets £100, 0 employees
- Moh TADAYYON appointedDirector
- Maria THANOU appointedDirector
- Dr Moh Tadayyon registered as a person with significant control
- Prof. Maria Thanou registered as a person with significant control
- Company incorporatedPrivate limited company
Dates as recorded at Companies House: incorporation, name changes, officer appointments and resignations, current and former persons with significant control, and the end of each financial year with figures in the database.